Clinical Trials

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT06706219 2026-04-03

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07480733 2026-03-25

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

480 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Pancreatic Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT05888402 2026-02-27

InTRist

50 enrolled

Local Advanced Non-small Cell Lung Cancer

NCT07410234 2026-02-13

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

110 enrolled

Breast Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Oropharyngeal Neoplasms

NCT04418648 2026-02-04

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Phase 2 Terminated

170 enrolled

Small Cell Lung Cancer Limited Stage

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07342322 2026-01-15

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

25 enrolled

Sarcoma

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

35 enrolled

Triple Negative Breast Neoplasms

NCT06416696 2026-01-02

Toripalimab for High-risk Locally Advanced Cervical Cancer

57 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07309276 2025-12-30

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

864 enrolled

Advanced Lung Cancer

NCT06584435 2025-12-19

TUORA

100 enrolled

High-risk Renal Cell Carcinoma

NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

45 enrolled

Muscle-invasive Bladder Urothelial Carcinoma

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

40 enrolled

Non-small Lung Cancer

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07272291 2025-12-09

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT06735131 2025-12-03

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

60 enrolled

Triple Negative Breast Neoplasms

NCT05975307 2025-12-01

BCIRT-01

71 enrolled

Urinary Bladder Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

41 enrolled

Triple Negative Breast Neoplasms

NCT03926338 2025-11-20

PICC

270 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT07201675 2025-10-01

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

59 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07140679 2025-09-25

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

40 enrolled

Colonic Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07172386 2025-09-16

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

40 enrolled

Carcinoma, Renal Cell

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT06127303 2025-09-05

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Breast Neoplasms

NCT07106034 2025-08-12

ONTOP

32 enrolled

Colorectal Neoplasms

NCT07039656 2025-08-07

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

211 enrolled

Stage IB-IIIB NSCLC

NCT07110558 2025-08-07

PUPA

59 enrolled